BioMarin, MSD sue Aurobindo over rare disease drug

BioMarin Pharmaceutical and MSD (known as 'Merck & Co' in the US), have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan (Sapropterin hydrochloride), used to treat a rare genetic disorder.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

23 November 2021 BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

BioMarin, MSD sue Aurobindo over rare disease drug

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features